Biocompatibility assessments for medical devices – evolving regulatory considerations

References

• Use of International Standard ISO-10993. Biological valuation of Medical Devices Part 1: Evaluation and Testing. Final Guidance for Industry and Food and Drug Administration Staff, US Dept. of Health and Human Services, FDA, Center for Devices and Radiological Health, Office of Device Evaluation. Jun 16 2016.
   Google Scholar
• Use of international standard ISO-10993, ‘biological evaluation of medical devices part 1: evaluation and testing’. ODE general program memorandum #G95-1. director, office of device evaluation (ODE), FDA. 1995 May 1.
   Google Scholar
• Use of International Standard ISO-10993. Biological Evaluation of Medical Devices Part 1: evaluation and Testing. Draft Guidance for Industry and Food and Drug Administration Staff, US Dept. of Health and Human Services, FDA, Center for Devices and Radiological Health, Office of Device Evaluation. 2013 Apr 23.
   Google Scholar
• Standards and projects under the direct responsibility of the International standards organisation technical committee 194 secretariat. cited Jul 2016. Available from: http://www.iso.org/iso/home/store/catalogue_tc/catalogue_tc_browse.htm?commid=54508
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 1: evaluation and testing within a risk management process, International Standard ISO 10993-1. 4th edition 2009 Oct 15.
   Google Scholar
• International Organisation for Standardisation, Biological Evaluation of Medical Devices – Part 12: Sample preparation and reference materials, ISO 10993 – Part 12. 4th Edition 2012 Jun 29.
   Google Scholar
• International organisation for standardisation, cardiovascular biological evaluation of medical devices – guidance for absorbable implants. ISO technical report 37137. 1st Edition 2014 May 15.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 5: tests for in vitro cytotoxicity. 2rd edition 2009 Jun 1.
   Google Scholar
• Reeve L, Baldrick P. Biocompatibility testing for medical devices – trouble ahead? Regulatory Rapporteur. 2013;10(11):25–28.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 10: tests for irritation and skin sensitization. 3rd edition 2010 Aug 1.
   Google Scholar
• Organisation for economic cooperation and development guideline for the testing of chemicals, skin sensitization: local lymph node assay, Test Guideline 429 Adopted. 22 Jul 2010.
   Google Scholar
• Organisation for economic cooperation and development guideline for the testing of chemicals, skin sensitization: local lymph node assay: DA test guideline 442A adopted. 2010 Jul 22.
   Google Scholar
• Organisation for economic cooperation and development guideline for the testing of chemicals, skin sensitization: local lymph node assay: BrdU-ELISA. Test Guideline 442B Adopted. 2010 Jul 22.
   Google Scholar
• Organisation for economic cooperation and development guideline for testing of chemicals, skin sensitisation, test guideline 406, adopted by the council. 1992 Jul 17.
   Google Scholar
• Organisation for economic cooperation and development guideline for the testing of chemicals, skin sensitization: local lymph node assay test guideline 429, adopted. 2010 Jul 22.
   Google Scholar
• Organisation for Economic Cooperation and Development Guideline For The Testing of Chemicals. In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA), Test Guideline 442C, Adopted. 2015 Feb 4.
   Google Scholar
• Organisation for Economic Cooperation and Development Guideline For The Testing of Chemicals. In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method, Test Guideline 442D, Adopted. Feb 2015.
   Google Scholar
• Organisation for economic cooperation and development guideline for the testing of chemicals. In Vitro Skin Sensitisation: human Cell Line Activation Test (h-CLAT), Test Guideline 442E, Adopted. 29 Jul 2016.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 4: selection of tests for interaction with blood. 2nd edition 2002 15. Amendment 1 2006-07-15.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 33: guidance on tests to evaluate genotoxicity – supplement to ISO 10993-3. 1st edition 2015 Mar 1.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 3: tests for genotoxicity, carcinogenicity and reproductive toxicity. 3rd edition 2014 Oct 1.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 6: tests for effects after implantation. 2nd edition 2007 Apr 15.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 16: toxicokinetic study design for degradation products and leachables. 2nd edition 2010 Mar 31.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 9: framework for identification and quantification of potential degradation products. 2nd edition 2009 Dec 15.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 13: identification and quantification of degradation products from polymeric medical devices. 2nd edition 2010 Jun 15.
   Google Scholar
• International organisation for standardisation, biological evaluation of medical devices – part 14: identification and quantification of degradation products from ceramics. Edition 1 Published 2001 Nov 15.
   Google Scholar
• International Organisation for Standardisation, Biological Evaluation of Medical Devices – Part 15: identification and quantification of degradation products from metals and alloys. Edition 1 Published 2000 Dec 1.
   Google Scholar
• International conference on the harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. M7. Step 4. [ cited 23 Jun 2014].
   Google Scholar
• McGovern. PQRI Workshop on PQRI Workshop on Leachables andExtractables Leachables and Extractables, Rockville, Maryland, Dec 6, 2005.
   Google Scholar
• Paskiet D, Ball DJ, Jenke D, et al. The product quality researchInstitute (PQRI) leachables and extractables working group initiatives for parenteral and ophthalmic drug product (PODP). Parenteral Drug Association (PDA) Journal Ofpharmaceutical Science and Technology. 2013;67:430–447.
   Google Scholar
• Houston CT. The PQRI PODP approach: understanding threshold concepts and their application to different routes of administration. Podium presentation at: Smithers Rapra, E&L Europe 2015.
   Google Scholar